XTX Topco Ltd Invests $202,000 in Avanos Medical, Inc. (NYSE:AVNS)

XTX Topco Ltd bought a new stake in shares of Avanos Medical, Inc. (NYSE:AVNSFree Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,154 shares of the company’s stock, valued at approximately $202,000.

Several other large investors have also added to or reduced their stakes in AVNS. EntryPoint Capital LLC lifted its position in shares of Avanos Medical by 97.6% in the 1st quarter. EntryPoint Capital LLC now owns 5,601 shares of the company’s stock worth $112,000 after purchasing an additional 2,766 shares during the period. Janney Montgomery Scott LLC increased its position in Avanos Medical by 19.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 13,010 shares of the company’s stock valued at $259,000 after buying an additional 2,082 shares in the last quarter. Pitcairn Co. raised its position in shares of Avanos Medical by 11.2% in the 1st quarter. Pitcairn Co. now owns 15,940 shares of the company’s stock worth $317,000 after purchasing an additional 1,606 shares during the last quarter. Keene & Associates Inc. raised its holdings in Avanos Medical by 16.1% in the second quarter. Keene & Associates Inc. now owns 18,635 shares of the company’s stock worth $371,000 after buying an additional 2,585 shares during the last quarter. Finally, Natixis Advisors LLC lifted its position in Avanos Medical by 19.5% in the 2nd quarter. Natixis Advisors LLC now owns 18,878 shares of the company’s stock valued at $376,000 after acquiring an additional 3,077 shares in the last quarter. Institutional investors own 95.17% of the company’s stock.

Avanos Medical Stock Performance

Shares of NYSE AVNS opened at $23.77 on Monday. The company has a quick ratio of 1.49, a current ratio of 2.28 and a debt-to-equity ratio of 0.13. Avanos Medical, Inc. has a 52-week low of $17.24 and a 52-week high of $25.36. The company has a market cap of $1.09 billion, a PE ratio of -17.87 and a beta of 0.91. The firm’s 50-day moving average price is $23.48 and its 200-day moving average price is $20.99.

Avanos Medical (NYSE:AVNSGet Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.29 by $0.05. Avanos Medical had a return on equity of 4.48% and a net margin of 1.13%. The firm had revenue of $171.70 million during the quarter, compared to analyst estimates of $170.67 million. During the same period in the prior year, the business posted $0.24 EPS. Avanos Medical’s revenue was up 1.4% on a year-over-year basis. As a group, analysts anticipate that Avanos Medical, Inc. will post 1.39 EPS for the current year.

About Avanos Medical

(Free Report)

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.

Further Reading

Institutional Ownership by Quarter for Avanos Medical (NYSE:AVNS)

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.